Plain-English translation of NCT06006403 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing CD123-targeted CAR-NK cells — a new type of immune cell therapy that has been engineered in the laboratory to recognize and attack cancer cells. The treatment is designed for people whose blood cancers have come back after other treatments or haven't responded to standard chemotherapy. Researchers want to find the safest and most effective dose of these cells and see how well this medication works for two specific types of blood cancer.
Some blood cancers don't respond well to standard treatments or return even after patients have had chemotherapy. This study exists because doctors need new options for patients whose cancers are difficult to treat, and engineered immune cells offer a promising new approach.
You likely qualify if…
You likely don't qualify if…
You will receive infusions of the specially engineered immune cells through an intravenous line. The study starts with a dose-finding phase where a small group of patients receive low doses, then gradually higher doses are tested to find the safest level. Once researchers identify a safe dose, more patients will receive that dose in an expansion phase. You will have regular blood tests, imaging scans, and clinic visits to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China